Sterling is a pharmaceutical contract development and manufacturing organisation (CDMO) with over 50 years of experience.
From small molecules and antibody drug conjugates (ADCs) to peptides, Sterling can provide expert CDMO services spanning drug discovery, through development to commercial manufacture.
Our CDMO capabilities
As a pharmaceutical CDMO, Sterling offers a range of contract drug substance services and technologies, including:
Small molecule CDMO services:
- Drug discovery
- API development
- API manufacturing
- Early scale up
- API analytical services
- Solid state chemistry
- Milling and micronisation
- Hazard evaluation
- Chiral chemistry
- Hazardous chemistry
- Diazomethane
- Continuous/Flow
- Biocatalysis
- High potency APIs (HPAPIs)
- Controlled substances
- Mass spectrometry
ADC CDMO services:
- ADC development
- ADC clinical manufacturing
- ADC analytical services
- Mass spectrometry
Peptide CDMO services:
- Peptide development, manufacturing and analysis
Fast Facts
Six CDMO sites across the US, UK and EU.
8,850 experiments performed across the Sterling network over the last year.
>100 new product introduction stages per year.
57% of current projects are operating across multiple sites within the Sterling network.
GMP campaigns ranging from <1kg to more than 300 MT a year.
835m3 total reactor volume, producing over 700,000kg in more than 2,000 batches every year, across our western network.
10L to 6,300L hydrogenation capacity at pressures from 4 psig/0.28 bar to 1000 psig/69 bar.
Why choose Sterling as your CDMO partner?
Our decades of experience and commitment to being flexible and easy to do business with, combined with our global network of integrated facilities and range of experts, allow us to be responsive to your needs, exactly when and where you need us.
Sterling is the CDMO who recognises it’s never just a molecule to you. It’s late nights, doubts you have pushed through. It’s documentation and detail, day in and day out. We know what it’s taken to get this far, and we know what it takes to go further.
It’s always been about more than molecules to us too, and it’s never been just a contract. That’s what makes us more than a traditional CDMO. We are a PDMO®, or partnership development and manufacturing organisation.
Introducing PDMO: More than a traditional CDMO
Our customers and their projects have never been just another contract between businesses; it will always be a partnership between people who are working to achieve a better future for patients who need life-changing medicines.
That’s why referring to ourselves as a contract development and manufacturing organisation (CDMO) doesn’t feel like it truly represents who we are or how we do business. So, in 2020, we trademarked the term PDMO®, or partnership development and manufacturing organisation.
CDMO FAQs
What is a CDMO?
CDMO stands for contract development and manufacturing organisation, a company who provides contract pharmaceutical services to a range of pharmaceutical and biotechnology organisations.
How is a CDMO different from a CMO?
Whereas a CDMO is a contract development and manufacturing organisation, CMO stands for contract manufacturing organisation.
- A CMO will only provide contract manufacturing services
- A CDMO will provide a combination of contract development and manufacturing services
What is a PDMO pharma?
A PDMO® within the pharmaceutical industry refers to a partnership development and manufacturing organisation.
The term was coined and trademarked by CDMO Sterling Pharma Solutions in 2020 to better represent the way the organisation conducts business with its customers, going beyond the traditional contract to instead develop true scientific partnerships.
Related Content
Blog
The critical role of secondary suppliers in API manufacturing: Strategic priorities when selecting a drug substance CDMO
Quality and Regulatory
